STOCK TITAN

ANI Pharmaceuticals Inc - ANIP STOCK NEWS

Welcome to our dedicated news page for ANI Pharmaceuticals (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on ANI Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ANI Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ANI Pharmaceuticals's position in the market.

Rhea-AI Summary
ANI Pharmaceuticals, Inc. (ANIP) has announced the launch of Levofloxacin Oral Solution, a generic version of Levaquin®, aiming to tap into the $7.1 million U.S. market. The company emphasizes its commitment to growth in the Generics business and patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
none
-
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (ANIP) reported strong financial results for Q4 and full year 2023, with quarterly net revenues of $131.7 million, a 39.7% YoY growth, and adjusted non-GAAP EBITDA of $30.2 million. The Rare Disease business saw significant growth, with Q4 net revenues of $41.7 million, a 40.4% QoQ increase. ANIP ended the year with $221.1 million in cash and issued a 2024 guidance with net revenues of $520 million to $542 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.26%
Tags
earnings
-
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (ANIP) will present at the Leerink Partners Global Biopharma Conference in Miami Beach on March 12, 2024, at 2:20 p.m. ET. The webcast will be available on their website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences
Rhea-AI Summary
ANI Pharmaceuticals, Inc. will release its fourth quarter and full year 2023 financial results on February 29, 2024. The conference call will be hosted by President and CEO Nikhil Lalwani and CFO Stephen P. Carey. The call will be available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
earnings
-
Rhea-AI Summary
ANI Pharmaceuticals, Inc. CEO Nikhil Lalwani will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York City on Thursday, February 8, 2024, at 10:30 a.m. ET. The webcast will be accessible from the Company’s website, and a replay will be available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
conferences
-
Rhea-AI Summary
ANI Pharmaceuticals, Inc. announced the launch of Pentoxifylline ER Tablets, the generic version of the Reference Listed Drug Trental®, with an estimated annual U.S. market of $19.7 million. The company aims to drive growth through new product launches, operational excellence, and supply reliability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
Rhea-AI Summary
ANI Pharmaceuticals, Inc. received FDA approval for the Abbreviated New Drug Application for Indomethacin Oral Suspension, a generic version of the Reference Listed Drug Indocin® Oral Suspension. The U.S. market for Indomethacin OS is valued at $4.1 million annually. The FDA granted Indomethacin OS a Competitive Generic Therapy designation with 180-day exclusivity. ANI holds the second highest number of CGT approvals in the U.S. Generics market, showcasing their strong R&D capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
fda approval
-
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (ANIP) will be represented by President & CEO Nikhil Lalwani at the Piper Sandler 35th Annual Healthcare Conference in New York City on November 28, 2023. The webcast of the event will be available on the company's website, and 1x1 meetings can be scheduled by contacting corporateaccess@psc.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
conferences
-
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced record quarterly net revenues of $131.8 million, a 57.3% year-over-year growth, with net income available to common shareholders of $9.5 million and diluted GAAP income per share of $0.45. The company raised its full year 2023 guidance for net revenue to $468 million to $478 million and adjusted non-GAAP EBITDA to $128 million to $133 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.64%
Tags
earnings
Rhea-AI Summary
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) will participate in two upcoming healthcare conferences: Truist Securities BioPharma Symposium on November 9, 2023, and Jefferies London Healthcare Conference on November 15, 2023. The company's CEO and CFO will be attending and available for 1x1 meetings. The webcast of the conferences will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
conferences
ANI Pharmaceuticals Inc

Nasdaq:ANIP

ANIP Rankings

ANIP Stock Data

1.47B
14.70M
10.1%
75.16%
1.24%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Baudette

About ANIP

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.